TScan Therapeutics Files 2024 Proxy Statement

TL;DR

TScan Proxy Statement is IN: Vote on directors & auditors for 2024 meeting on June 12.

AI Summary

TScan Therapeutics, Inc. filed its definitive proxy statement for the 2024 Annual Meeting of Stockholders, scheduled for June 12, 2024. The filing, made on April 30, 2024, outlines the agenda and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of the independent registered public accounting firm.

Why It Matters

This filing is crucial for shareholders as it details the proposals they will vote on, influencing the company's future direction and corporate governance.

Risk Assessment

Risk Level: low — This is a routine annual filing providing information to shareholders and does not inherently introduce new risks.

Key Numbers

• 2024 — Annual Meeting Year (Year of the shareholder meeting)
• June 12 — Meeting Date (Date of the 2024 Annual Meeting of Stockholders)

Key Players & Entities

• TScan Therapeutics, Inc. (company) — Registrant
• 2024 Annual Meeting of Stockholders (event) — Meeting date
• June 12, 2024 (date) — Annual Meeting date
• April 30, 2024 (date) — Filing date
• 880 Winter Street, Waltham, MA 02451 (address) — Company address

FAQ

From the Filing

0001193125-24-125066.txt : 20240430 0001193125-24-125066.hdr.sgml : 20240430 20240430160728 ACCESSION NUMBER: 0001193125-24-125066 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240612 FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 24897177 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 DEF 14A 1 d693770ddef14a.htm DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 TSCAN THERAPEUTICS, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Table of Contents TSCAN THERAPEUTICS, INC. 830 Winter Street Waltham, MA 02451 NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS To be held June 12, 2024 Notice is hereby given that the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company” or “we”), will be held online on June 12, 2024, at 8:00 a.m. Eastern Time. You may attend the meeting virtually via the Internet at www.virtualshareholdermeeting.com/TCRX2024 , where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the Notice of Internet Availability of Proxy Materials being mailed to you separately in order to attend the Annual Meeting. The purpose of the Annual Meeting is the following: 1. To elect two Class III directors to the Company’s board of directors, each to serve until the 2027 annual meeting of stockholders and until such director’s successor has been duly elected and qualified, or until such director’s earlier death, resignation or removal; 2. To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; 3. To approve the Company’s Amended and Restated 2021 Equity Incentive Plan; and 4. To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. The proposal for the election of directors relates solely to the election of Class III directors nominated by the board of directors. Only the Company’s stockholders of record at the close of business on April 17, 2024, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. You can find more information on each of the matters to be voted on at the Annual Meeting, including information regarding the nominee for election to the Company’s board of directors, in the accompanying Proxy Statement. The board of directors recommends a vote